Japanese CRO Croee To Establish NPO To Accelerate Patient Enrollment Process
This article was originally published in PharmAsia News
Japanese contract research organization Croee plans to establish a non-profit organization to help enroll more clinical trial participants in Japan. As a third-party organization, the NPO will manage the database and protect individual privacy, promote public awareness of clinical trials and conduct follow-up activities such as providing information on new drugs after market launch. In Japan, medical facilities conducting clinical trials for pharmaceutical companies will ask site management organizations to start looking for patients to enroll in clinical studies. Croee hopes the new NPO will establish the patient database beforehand and will introduce candidates for certain trials to SMOs and hospitals. Croee has signed contracts with 50 SMOs and 500 hospitals. (Click here for more - Japanese language
You may also be interested in...
Cipla gets US FDA go-ahead earlier than anticipated for first generic of Merck’s Proventil, setting the stage for increased competition in the albuterol segment, where demand is up amid the coronavirus pandemic.
The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.
Shortly after wrapping up a Phase III trial for its proposed generic Advair Diskus product in the US, Cipla has won FDA approval for the first generic Proventil HFA product, as it continues to build up steam in the US respiratory market.